Altimmune, Inc. (NASDAQ: ALT) reported Q4 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $26 thousand versus the consensus estimate of $625 million.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.